Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 514-520

  Mackay, Ian ^a   Ford, Isobel ^b   Thies, Frank ^b   Fielding, Shona ^b   Bachoo, Paul ^a   Brittenden, Julie ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Intermittent claudication; Omega 3, platelet function; Pulse wave velocity; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; OMEGA 3 FATTY ACID; PADGEM PROTEIN; PLACEBO; VON WILLEBRAND FACTOR;

ADULT; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FEMALE; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SMOKING; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; P-SELECTIN; PERIPHERAL ARTERIAL DISEASE; PLACEBOS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PULSATILE FLOW; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84858701349     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.041     Document Type: Article

References (31)

1. Wood D., Durrington P., Poulter N., McInnes G., Rees A., Wray R. Joint British Recommendations on prevention of coronary heart disease in clinical practice. Heart 1998, 80(Suppl. 2):S1-S29.
2. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 345:447-455. Gissi-Prevenzione investigators.
3. Lean M.E.J., Anderson A.S., Morrison C., Currall J. Evaluation of a dietary targets monitor. Eur J Clin Nutr 2003, 57:667-673.
4. Mori T.A., Beilin L.J. Long-chain Omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001, 12.
5. Cassar K., Bachoo P., Brittenden J. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg 2003, 25(1):6-15.
6. Cassar K., Bachoo P., Ford I., Greaves M., Brittenden J. Platelet activation is increased in patients with peripheral arterial disease. J Vasc Surg 2003, 25:6-15.
7. Mori T.A., Beilin L.J., Burke V., et al. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997, 17:279-286.
8. Greaves M., Woodcock B.E., Galloway J.H., Preston F.E. Studies on the incorporation of eicosapentaenoic acid (EPA) into platelet membrane phospholipids and the effects of EPA supplementation on platelet function, skin bleeding time and blood viscosity in man. Br J Clin Pract 1984, 38:45-48.
9. Woodcock B.E., Smith E., Lambert W.J., et al. Beneficial effect of fish oil on blood viscosity in peripheral vascular disease. Br Med J 1984, 288:592-594.
10. Cartwright I.J., Pockley A.G., Galloway J.H., Greaves M., Preston F.E. The effects of dietary w-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985, 55:267-281.
11. Lip G.T.H., Von Blann A.D. Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995, 74:580-583.
12. Johansen O., Seljeflot I., Hostmark A.T., Arnesen H. The effect of supplementation with Omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 1999, 19:1681-1686.
13. Selijeflot I., Arnesen H., Brude I.R., et al. Effect of Omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest 1998, 28:629-635.
14. Cao J., Schwichtenberg K.A., Hanson N.Q., Tsai M.Y. Incorporation and clearance of Omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 2006, 52:2265-2272.
15. Bligh E.G., Dyer W.J. A rapid method for total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
16. Rajagopalan S., Ford I., Bachoo P., et al. Platelet activation, myocardial ischaemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. JTH 2007, 5:2028-2035.
17. Meiklejohn D.J., Vickers M.A., Morrison E.R., et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001, 112:621-631.
18. Collins P., Ford I., Greaves M., Macaulay E., Brittenden J. Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state. Platelets 2006, 17:311-317.
19. Smith J.W., Steinhubl S.R., Lincoff A.M., et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999, 99:620-625.
20. Harrison P. Platelet function analysis. Blood Rev 2005, 19:111-123.
21. Matzdorff A.C., Kuhnel G., Kemkes-Matthes B., Voss R. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis 2001, 12:129-139.
22. Yasmin, Brown M.J. Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. Q Med J 1999, 92:595-600.
23. Jones B., Kenward M.G. Design and analysis of cross-over trials. 1989, Chapman and Hall, London.
24. Brown H., Prescott R. Applied mixed models in medicine. 1989, Wiley, Chichester.
25. Zarbock A., Polanowska-Grabowska R.K., Ley K. Platelet-neutrophil interactions: linking haemostasis and inflammation. Blood Rev 2007, 21:99-111.
26. Smith F.B., Lee A.J., Hau C.M., Rumley A., Lowe G.D., Fowkes F.G. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis 2000, 11:43-50.
27. Gajos G., Rostoff P., Undas A., Piwowarska W. Effects of polyunsaturated fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the Omega-PCI (Omega-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy). Study J Am Coll Cardiol 2010, 55:1671-1678.
28. Cassar K., Bachoo P., Ford I., Greaves M., Brittenden J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Br J Surg 2004, 91:50.
29. Schiano V., Laurenzano E., Brevetti G., et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile and endothelial function. Clin Nutr 2008, 27:241-247.
30. Laurent S., Cockcroft J., Bortel L.V., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
31. Sommerfield T., Price J., Hiatt W.R. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2007, (4):CD003833.